Evaluation of combined adjuvant vis-Ã -vis single adjuvant for development of caprine pleuropneumonia vaccine in goats using indigenous Mycoplasma mycoides subsp. capri isolate

Abstract

The disease caprine pleuropneumonia is endemic and is      of serious concern in goats in India. The etiological agent
Mycoplasma mycoides subsp. capri, widely prevalent in  Asia  and other parts of the world. The organism causes pneumonia outbreaks in goats. In this experiment, an attempt was made to develop killed Mycoplasma mycoides subsp. capri vaccine. The trial was conducted with saponin (vaccine A) and saponin + aluminium hydroxide (vaccine B) as adjuvants incorporating 1.5 mg protein of sonicated Mycoplasma mycoides subsp. capri antigen in each preparation. Upon challenge at 12 month post inoculation, vaccine A and   B produced 75 and 100% protection, respectively. The result indicated the possibility   of vaccine B as future candidate vaccine for caprine pleuropneumonia. However, large scale field trial is warranted. Further, the vaccine was found to be superior over in use vaccines in terms of per cent protection, extended immunity, number     of immunization and minimum reaction at the site of inoculation.